{"filing":{"accession_number":"0001601830-26-000097","cik":"0001601830","ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"rxrx-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/rxrx-20260805.htm"},"events":[{"id":24921,"run_id":22594,"accession_number":"0001601830-26-000097","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Recursion disclosed its second quarter 2026 financial results on August 5, 2026, reporting revenue of $7.7 million, R\u0026D expenses of $89.6 million, G\u0026A expenses of $41.5 million, and a net loss of $131.0 million, along with a cash position of $556.8 million and comparative operational metrics.","company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25618,"accession_number":"0001601830-26-000097","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Recursion's second quarter 2026 financial results via a press release issued on August 5, 2026, including revenue ($7.7M), R\u0026D expenses ($89.6M), G\u0026A expenses ($41.5M), and net loss ($131.0M), along with cash position and operational metrics. This is a standard quarterly earnings release under Item 2.02, accompanied by condensed consolidated statements of operations showing comparative results for Q2 2026 vs. Q2 2025.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:35:26.930271+00:00","company_name":"","ticker":null,"filing_date":""},{"id":25619,"accession_number":"0001601830-26-000097","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Recursion's second quarter 2026 financial results, including revenue of $7.7 million, R\u0026D expenses of $89.6 million, net loss of $131.0 million, and cash position of $556.8 million. The press release (Exhibit 99.1) explicitly states \"Recursion Reports Second Quarter Financial Results\" and includes condensed consolidated statements of operations with detailed financial metrics. This is a standard quarterly earnings disclosure material to investors' assessment of the company's financial performance and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:35:26.930271+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25618,"accession_number":"0001601830-26-000097","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Recursion's second quarter 2026 financial results via a press release issued on August 5, 2026, including revenue ($7.7M), R\u0026D expenses ($89.6M), G\u0026A expenses ($41.5M), and net loss ($131.0M), along with cash position and operational metrics. This is a standard quarterly earnings release under Item 2.02, accompanied by condensed consolidated statements of operations showing comparative results for Q2 2026 vs. Q2 2025.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:35:26.930271+00:00","company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","filing_date":"2026-08-05"},{"id":25619,"accession_number":"0001601830-26-000097","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Recursion's second quarter 2026 financial results, including revenue of $7.7 million, R\u0026D expenses of $89.6 million, net loss of $131.0 million, and cash position of $556.8 million. The press release (Exhibit 99.1) explicitly states \"Recursion Reports Second Quarter Financial Results\" and includes condensed consolidated statements of operations with detailed financial metrics. This is a standard quarterly earnings disclosure material to investors' assessment of the company's financial performance and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:35:26.930271+00:00","company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","filing_date":"2026-08-05"}]}